Seeking Alpha

ZIOPHARM up 10% in early trading

  • Shares of ZIOPHARM Oncology (ZIOP +10.7%) get a post-report tailwind.
  • Investors like its collaboration with Intrexon (XON) for its RheoSwitch Therapeutic System, a method for modulating protein production in gene-based therapies.
  • The company's lead product, Ad-RTS-IL-12, a novel gene expression platform for interleukin-12, is currently in P2 trials for the treatment of melanoma and breast cancer.
  • Quick assets totaled $68.2M at years end and will be sufficient to fund operations into 2015's second quarter.
  • Earnings release
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector